Physician Survey to Assess Effectiveness of Strattera Risk Minimisation Activities in Prescribers Treating Adult Patients with ADHD

Study identification

• EU PAS number:
  EUPAS6486
• Study ID:
  20488
• Official title and acronym:
  Physician Survey to Assess Effectiveness of Strattera Risk Minimisation Activities in Prescribers Treating Adult Patients with ADHD
• DARWIN EU® study:
  No
• Study countries:
  Denmark

  Netherlands

  Spain

  Sweden

  United Kingdom
• Study description:
  This is a cross-sectional survey to be administered in Denmark, Sweden, the Netherlands, Spain, and the UK among psychiatrists who prescribe Strattera and/or monitor adult patients treated with Strattera.
• Study status:
  Finalised

Research institutions and networks

Institutions

GfK Health

Study timelines

Date when funding contract was signed

Planned:03/02/2014

Actual:03/02/2014

Study start date

Planned:27/06/2014

Actual:27/06/2014

Date of final study report

Planned:30/01/2015

Actual:20/11/2014

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)